Home LiteratureArticle Details
PMID: 21335512 Published · ppublish English Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria.

Journal of the American Society of Nephrology : JASN ·Vol. 22 ·No. 3 ·2011-03-00 ·Pages 537-44

Forsblom C, Harjutsalo V, Thorn LM, Wadén J, Tolonen N, Saraheimo M, Gordin D, Moran JL, Thomas MC, Groop PH, FinnDiane Study Group

Abstract

Patients with both type 1 diabetes and CKD have an increased risk of adverse outcomes. The competing risks of death and ESRD may confound the estimates of risk for each outcome. Here, we sought to determine the major predictors of the cumulative incidence of ESRD and pre-ESRD mortality in patients with type 1 diabetes and macroalbuminuria while incorporating the competing risk for the alternate outcome into a Fine-Gray competing-risks analysis. We followed 592 patients with macroalbuminuria for a median of 9.9 years. During this time, 56 (9.5%) patients died and 210 (35.5%) patients developed ESRD. Predictors of incident ESRD, taking baseline renal function and the competing risk for death into account, included an elevated HbA(1c), elevated LDL cholesterol, male sex, weight-adjusted insulin dose, and a shorter duration of diabetes. By contrast, predictors of pre-ESRD death, taking baseline renal function and the competing risk for ESRD into account, included only age, the presence of established macrovascular disease, and elevated cholesterol levels. This competing-risks approach has potential to highlight the appropriate targets and strategies for preventing premature mortality in patients with type 1 diabetes.

MeSH Terms
Adult Albuminuria/complications,epidemiology Comorbidity Diabetes Mellitus, Type 1/complications,epidemiology Diabetic Nephropathies/epidemiology,mortality Female Humans Incidence Kidney Failure, Chronic/epidemiology,mortality Male Middle Aged Prospective Studies Risk Factors Survival Rate
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Forsblom Carol
Folkhälsan Research Center, Biomedicum Helsinki, Haartmaninkatu 8, University of Helsinki, Finland.
Harjutsalo Valma
Thorn Lena M
Wadén Johan
Tolonen Nina
Saraheimo Markku
Gordin Daniel
Moran John L
Thomas Merlin C
Groop Per-Henrik
FinnDiane Study Group
References (24)
24 references, click to expand
  1. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
    N Engl J Med. 2005 Dec 22;353(25):2643-53 PMID: 16371630
  2. Risk for ESRD in type 1 diabetes remains high despite renoprotection.
    J Am Soc Nephrol. 2011 Mar;22(3):545-53 PMID: 21355053
  3. Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes.
    Diabetes Care. 1999 Jul;22(7):1165-70 PMID: 10388983
  4. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.
    Ann Intern Med. 2006 Aug 15;145(4):247-54 PMID: 16908915
  5. Endothelial vasodilator function is related to low-density lipoprotein particle size and low-density lipoprotein vitamin E content in type 1 diabetes.
    J Am Coll Cardiol. 2000 Feb;35(2):292-9 PMID: 10676672
  6. Long-term predictors of coronary artery disease and mortality in type 1 diabetes.
    QJM. 2001 Nov;94(11):623-30 PMID: 11704692
  7. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models.
    JAMA. 2001 Sep 26;286(12):1494-7 PMID: 11572743
  8. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study.
    Diabetes Care. 2003 May;26(5):1374-9 PMID: 12716791
  9. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes.
    Diabetes. 2009 Jul;58(7):1651-8 PMID: 19401416
  10. Hypercholesterolemia--a determinant of renal function loss and deaths in IDDM patients with nephropathy.
    Kidney Int Suppl. 1994 Feb;45:S125-31 PMID: 8158881
  11. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study).
    Diabetes Care. 2005 Aug;28(8):2019-24 PMID: 16043748
  12. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study.
    BMJ. 1996 Sep 28;313(7060):779-84 PMID: 8842069
  13. Survival methods, including those using competing risk analysis, are not appropriate for intensive care unit outcome studies.
    Crit Care. 2006 Feb;10(1):103 PMID: 16420653
  14. A note on including time-dependent covariate in regression model for competing risks data.
    Biom J. 2005 Dec;47(6):807-14 PMID: 16450853
  15. Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes.
    Diabetes. 2008 Sep;57(9):2480-7 PMID: 18544706
  16. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.
    Stat Med. 1999 Mar 30;18(6):695-706 PMID: 10204198
  17. Actual and actuarial probabilities of competing risks: apples and lemons.
    Ann Thorac Surg. 2007 May;83(5):1586-92 PMID: 17462363
  18. Predictors of mortality and end-stage diabetic complications in patients with Type 1 diabetes mellitus on intensified insulin therapy.
    Diabet Med. 2000 Oct;17(10):727-34 PMID: 11110506
  19. Time-dependent covariates in the proportional subdistribution hazards model for competing risks.
    Biostatistics. 2008 Oct;9(4):765-76 PMID: 18434297
  20. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.
    Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266 PMID: 11904577
  21. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    N Engl J Med. 2008 Jun 12;358(24):2560-72 PMID: 18539916
  22. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Am J Kidney Dis. 2009 Nov;54(5):810-9 PMID: 19540640
  23. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
    Lancet. 2008 Jan 12;371(9607):117-25 PMID: 18191683
  24. Analysing and interpreting competing risk data.
    Stat Med. 2007 Mar 15;26(6):1360-7 PMID: 16900575
Article Info
Journal
Journal of the American Society of Nephrology : JASN
Abbr.
J Am Soc Nephrol
ISSN
1533-3450
Published
2011-03-00
Epub
2011-00-18
Pages
537-44
Language
English
Region
United States
NLM ID
9013836
PMCID
PMC3060447
Subset
IM
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com